Filgotinib Is an Effective and Safe Treatment Option for Difficult-To-Treat Ulcerative Colitis: Real-World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry

Inflammatory Bowel Disease

Treat-to-target optimization of biologic therapy is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis-the TACTIC-UC study

J Crohns Colitis

Privitera G, Bezzio C, Buono AD, Gabbiadini R, Loy L, Ranucci L, Bertin L, Masoni B, Migliorisi G, Sauta E, Delleani M, Savevski V, Porta MD, D'amico S, Armuzzi A

doi: 10.1093/ecco-jcc/jjaf239

Inflammatory Bowel Disease

Real-world Effectiveness of Ustekinumab Versus Anti-TNF or Vedolizumab in Ulcerative Colitis: Induction and 12-Month Maintenance Results from the Prospective, Observational RUN-UC Study

J Crohns Colitis

Bokemeyer B, Plachta-Danielzik S, Gilman E, Howaldt S, Mohl W, Efken P, Ehehalt R, Kahl M, Krause T, Trentmann L, Lügering A, Schnoy E, Jochum C, Hartmann P, Schreiber S

doi: 10.1093/ecco-jcc/jjaf052

Inflammatory Bowel Disease

Real-world comparison of the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis: the TORUS study

Clin Gastroenterol Hepatol

Buisson A, Serrero M, Altwegg R, Guilmoteau T, Bouguen G, Nachury M, Amiot A, Vuitton L, Treton X, Caillo L, Pereira B, Fumery M

doi: 10.1016/j.cgh.2025.07.044

Inflammatory Bowel Disease

Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data

BMC Gastroenterol

Dignass A, Teich N, Kaiser S, Sünwoldt J, Dünweber C, Weinhold I, Borchert J, Kudernatsch R

doi: 10.1186/s12876-025-04022-7

Inflammatory Bowel Disease

Gaps between European Crohn's Colitis Organisation quality standards of care and the real world on structure of IBD units across Europe: results from E-QUALITY survey

J Crohns Colitis

Fiorino G, Walsh A, Adamina M, Barreiro-Acosta M, Ali MP, Bortlik M, Burisch J, Dignass A, Drobne D, Faiz O, Ferrante M, Fierens L, Godny L, Gojdicova A, Iacucci M, Jӓghult S, Karmiris K, Kirchgesner J, Restellini S, Rosini F, Shouval D, Van Deen W, Yanai H, Zagórowicz E, Fidalgo C, European Crohn’s Colitis Organisation

doi: 10.1093/ecco-jcc/jjaf094

RECOMMENDED

Inflammatory Bowel Disease

Gaps between European Crohn's and Colitis Organisation quality standards of care and the real world on diagnosis and monitoring inflammatory bowel disease across Europe: results from the E-QUALITY survey

★ 3 Recommended by Prof. Dr Stephan Vavricka, Faculty Member

J Crohns Colitis

Fiorino G, Fidalgo C, Adamina M, Barreiro-de Acosta M, Ali MP, Bortlik M, Burisch J, Dignass A, Drobne D, Faiz O, Ferrante M, Fierens L, Godny L, Gojdicova A, Iacucci M, Jӓghult S, Karmiris K, Kirchgesner J, Restellini S, Rosini F, Shouval D, Yanai H, Zagórowicz E, Walsh A, European Crohn’s Colitis Organisation

doi: 10.1093/ecco-jcc/jjaf105

Inflammatory Bowel Disease

Establishing a Multiple Outcome Set for Crohn's Disease in Real-World Evidence Studies: Results from a Delphi e-Survey

J Crohns Colitis

Moreira PL, Dignass A, Estevinho MM, Santiago M, Reinisch W, Sands BE, D'Haens G, Mantzaris GJ, Danese S, Peyrin-Biroulet L, Dotan I, Jairath V, Magro F, International Organization for the Study of Inflammatory Bowel Diseases (IOIBD)

doi: 10.1093/ecco-jcc/jjaf178

RECOMMENDED

Further Publications

Real-world effectiveness of advanced therapies in microscopic colitis

★ 2 Recommended by Prof. Dr Stephan Vavricka, Faculty Member

Clin Gastroenterol Hepatol

Verstockt B, Taelman T, Din S, Vavricka SR, Blesl A, Zabana Y, Van Moerkercke W, Kiudelis V, de la Revilla Negro J, Maillard MH, Savarino EV, Teich N, Macaigne G, Truyens M, Ribaldone DG, Barreiro-de Acosta M, Wildt S, Rivière P, Fumery M, Amiot A, Marsal J, Tontini GE, Levartovsky A, Vieujean S, Somers M, Cremer A, Lutakov I, Cohen NA, Dewit S, Bajer L, Rahier JF, Backman AS, Nancey S, Choden T, Van Dongen J, Rogler G, Lenfant M, Finlayson M, Münch A, Julsgaard M

doi: 10.1016/j.cgh.2025.12.019

Inflammatory Bowel Disease

Thromboembolic Risk in Ulcerative Colitis Patients on Advanced Therapy: A Real-World Data Analysis

Inflamm Bowel Dis

Nishida Y, Hosomi S, Fujimoto K, Kobayashi Y, Nakata R, Maruyama H, Ominami M, Nadatani Y, Fukunaga S, Otani K, Tanaka F, Fujiwara Y

doi: 10.1093/ibd/izaf302

Related content

Treat-to-target optimization of biologic therapy is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis-the TACTIC-UC study

Real-world Effectiveness of Ustekinumab Versus Anti-TNF or Vedolizumab in Ulcerative Colitis: Induction and 12-Month Maintenance Results from the Prospective, Observational RUN-UC Study

Real-world comparison of the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis: the TORUS study

Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data

Gaps between European Crohn's Colitis Organisation quality standards of care and the real world on structure of IBD units across Europe: results from E-QUALITY survey

Gaps between European Crohn's and Colitis Organisation quality standards of care and the real world on diagnosis and monitoring inflammatory bowel disease across Europe: results from the E-QUALITY survey

Establishing a Multiple Outcome Set for Crohn's Disease in Real-World Evidence Studies: Results from a Delphi e-Survey

Real-world effectiveness of advanced therapies in microscopic colitis

Thromboembolic Risk in Ulcerative Colitis Patients on Advanced Therapy: A Real-World Data Analysis